221.65
-15.60
(-6.58%)
At close: January 10 at 3:48:23 PM GMT+5:30
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
86,390,700.00
81,064,100.00
70,324,100.00
64,715,000.00
28,997,500.00
Cost of Revenue
34,651,400.00
32,587,600.00
30,001,800.00
26,803,100.00
12,540,300.00
Gross Profit
51,739,300.00
48,476,500.00
40,322,300.00
37,911,900.00
16,457,200.00
Operating Expense
46,129,300.00
44,161,400.00
40,802,000.00
34,260,300.00
11,651,900.00
Operating Income
5,610,000.00
4,315,100.00
-479,700.00
3,651,600.00
4,805,300.00
Net Non Operating Interest Income Expense
-4,227,800.00
-4,365,700.00
-3,425,400.00
-1,975,700.00
159,900.00
Pretax Income
3,218,800.00
1,792,900.00
-1,201,500.00
4,849,800.00
6,867,800.00
Tax Provision
2,765,500.00
1,614,700.00
663,100.00
1,090,200.00
1,152,800.00
Net Income Common Stockholders
453,300.00
178,200.00
-1,864,600.00
3,759,600.00
5,715,000.00
Diluted NI Available to Com Stockholders
453,300.00
178,200.00
-1,864,600.00
3,759,600.00
5,715,000.00
Basic EPS
0.39
0.14
-1.54
3.09
4.70
Diluted EPS
0.39
0.14
-1.54
3.09
4.70
Basic Average Shares
1,317,871.03
1,281,104.37
1,212,672.65
1,216,975.69
1,216,975.69
Diluted Average Shares
1,320,276.35
1,283,509.69
1,212,672.65
1,216,975.69
1,216,975.69
Rent Expense Supplemental
--
315,900.00
321,000.00
282,500.00
110,000.00
Total Expenses
80,780,700.00
76,749,000.00
70,803,800.00
61,063,400.00
24,192,200.00
Net Income from Continuing & Discontinued Operation
453,300.00
178,200.00
-1,864,600.00
3,759,600.00
5,715,000.00
Normalized Income
693,050.00
417,950.00
-1,830,440.00
3,710,374.34
5,608,319.11
Interest Income
--
119,200.00
16,400.00
6,800.00
207,000.00
Interest Expense
4,331,600.00
4,469,500.00
3,377,100.00
1,887,800.00
--
Net Interest Income
-4,227,800.00
-4,365,700.00
-3,425,400.00
-1,975,700.00
159,900.00
EBIT
7,550,400.00
6,262,400.00
2,175,600.00
6,737,600.00
4,805,300.00
EBITDA
15,142,600.00
13,668,100.00
8,942,500.00
12,599,400.00
6,241,700.00
Reconciled Cost of Revenue
34,651,400.00
32,587,600.00
30,001,800.00
26,803,100.00
12,540,300.00
Reconciled Depreciation
7,592,200.00
7,405,600.00
6,766,900.00
5,861,800.00
609,600.00
Net Income from Continuing Operation Net Minority Interest
453,300.00
178,200.00
-1,864,600.00
3,759,600.00
5,715,000.00
Total Unusual Items Excluding Goodwill
-342,500.00
-342,500.00
-48,800.00
63,500.00
128,200.00
Total Unusual Items
-342,500.00
-342,500.00
-48,800.00
63,500.00
128,200.00
Normalized EBITDA
15,485,100.00
14,010,600.00
8,991,300.00
12,535,900.00
6,113,500.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-102,750.00
-102,750.00
-14,640.00
14,274.34
21,519.11
3/31/2021 - 10/19/2022
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
DIVISLAB.BO Divi's Laboratories Limited
5,766.25
-0.97%
RPGLIFE.BO RPG Life Sciences Limited
2,113.05
-4.82%
IPCALAB.BO Ipca Laboratories Limited
1,631.30
-1.80%
INDSWFTLTD.BO Ind-Swift Limited
28.09
-4.88%
PHARMAID.BO Pharmaids Pharmaceuticals Limited
81.65
-1.99%
SOLARA.BO Solara Active Pharma Sciences Limited
655.15
-3.89%
NECLIFE.BO Nectar Lifesciences Limited
37.60
-0.82%
INDSWFTLAB.BO Ind-Swift Laboratories Limited
107.25
-1.97%
BALAXI.NS Balaxi Pharmaceuticals Limited
72.14
-3.76%
BIOFILCHEM.NS Biofil Chemicals and Pharmaceuticals Limited
56.64
-2.09%